Publicacións nas que colabora con Ruth Vera García (24)

2023

  1. SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2718-2731

  2. What do patients and oncologists think about the evaluation and management of cancer-related anorexia-cachexia? The Quasar_SEOM study

    Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3479-3491

2021

  1. Controversies in the treatment of RAS wild-type metastatic colorectal cancer

    Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 827-839

  2. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

    Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231

  3. Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM)

    ESMO Open, Vol. 6, Núm. 2

  4. SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)

    Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 988-1000

2020

  1. Correction to: Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology (Clinical and Translational Oncology, (2020), 22, 6, (823-834), 10.1007/s12094-019-02211-x)

    Clinical and Translational Oncology

  2. Correlation of recist, computed tomography morphological response, and pathological regression in hepatic metastasis secondary to colorectal cancer: The avamet study

    Cancers, Vol. 12, Núm. 8, pp. 1-12

  3. Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?

    International Journal of Colorectal Disease, Vol. 35, Núm. 4, pp. 739-746

  4. Liquid biopsy in oncology: A consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Revista Espanola de Patologia, Vol. 53, Núm. 4, pp. 234-245

  5. Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 22, Núm. 6, pp. 823-834

  6. Maintenance treatment in metastatic colorectal cancer: in search of the best strategy

    Clinical and Translational Oncology, Vol. 22, Núm. 8, pp. 1205-1215

2019

  1. Optimization of oral chemotherapy in outpatient clinics in Spain: results from a survey of the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 21, Núm. 4, pp. 534-538

  2. Phase I/II trial to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with pancreatic cancer and an ECOG performance status of 2

    Journal of Clinical Oncology

2018

  1. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: The ANICE-PaC study

    BMC Cancer, Vol. 18, Núm. 1

2017

  1. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain

    Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 667-681

  2. Medical oncology future plan of the Spanish Society of Medical Oncology: challenges and future needs of the Spanish oncologists

    Clinical and Translational Oncology, Vol. 19, Núm. 4, pp. 508-518

2016

  1. SEOM Clinical Guideline for the treatment of pancreatic cancer (2016)

    Clinical and Translational Oncology, Vol. 18, Núm. 12, pp. 1172-1178

2013

  1. Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: Results from a randomized, phase II prospective trial

    Annals of Oncology, Vol. 24, Núm. 2, pp. 448-453

2012

  1. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

    PLoS ONE, Vol. 7, Núm. 10